MannKind FY2026 EPS Estimate Lowered by Leerink Partnrs

MannKind Co. (NASDAQ:MNKD) – Leerink Partnrs reduced their FY2026 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings of $0.22 per share for the year, down from their previous forecast of $0.23. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Other equities research analysts also recently issued research reports about the company. Royal Bank of Canada upgraded MannKind from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $7.00 to $10.00 in a research report on Thursday. Leerink Partners assumed coverage on shares of MannKind in a report on Monday, September 9th. They issued an “outperform” rating and a $8.00 price objective on the stock. StockNews.com lowered shares of MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. Finally, Oppenheimer boosted their price target on shares of MannKind from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $8.86.

MannKind Stock Performance

MNKD stock opened at $6.30 on Friday. MannKind has a one year low of $3.17 and a one year high of $7.63. The firm has a market cap of $1.74 billion, a PE ratio of 90.00 and a beta of 1.28. The firm’s 50 day moving average price is $6.75 and its 200-day moving average price is $6.01.

Insiders Place Their Bets

In related news, Director Steven B. Binder sold 67,539 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $6.76, for a total transaction of $456,563.64. Following the completion of the transaction, the director now directly owns 1,075,026 shares of the company’s stock, valued at $7,267,175.76. The trade was a 5.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Stuart A. Tross sold 55,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total value of $403,700.00. Following the completion of the sale, the insider now directly owns 967,191 shares in the company, valued at $7,099,181.94. This represents a 5.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 190,075 shares of company stock worth $1,325,587 over the last three months. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in MannKind during the 2nd quarter worth about $55,000. Brookstone Capital Management acquired a new stake in shares of MannKind during the 2nd quarter worth about $61,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in MannKind by 22.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,946 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,816 shares during the last quarter. Renaissance Technologies LLC acquired a new position in MannKind in the second quarter valued at approximately $67,000. Finally, Quantinno Capital Management LP purchased a new position in MannKind in the third quarter valued at approximately $85,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.